Diaceutics hopes to ‘super charge’ its offering in US market after CMS approval

  • 📰 IrishTimesBiz
  • ⏱ Reading Time:
  • 10 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 7%
  • Publisher: 77%

대한민국 뉴스 뉴스

대한민국 최근 뉴스,대한민국 헤드 라인

Irish data analytics company will receive US claims data more frequently via IrishTimesBiz

The data will help to provide enhanced insight into the testing landscape for precision medicine through Diaceutics’ DXRX diagnostic commercialisation platform. The increased frequency of data feed will will help Diaceutics’s pharma and diagnostic clients to understand the evolving testing landscape in almost real time, which should help drive faster access to the right treatment.said the step up in data access would help “supercharge” its service in the market.

“The most competitive companies in the diagnostic data space are those that not only can integrate very different large data sets but can deliver near real time customer insights,” he said.

 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 6. in KR

대한민국 최근 뉴스, 대한민국 헤드 라인